Increased AKI Risk with Vancomycin plus Piperacillin/Tazobactam in Pediatric Inpatients

Acute kidney injury occurred in 12% receiving vancomycin and concomitant piperacillin/tazobactam versus 4% receiving a different concomitant beta-lactam antibiotic.

Empirical treatment of suspected serious infections in hospitalized children frequently consists of administering vancomycin plus one or more other β-lactam antibiotics. To determine the risk for acute kidney injury (AKI) in children receiving this regimen, researchers retrospectively assessed AKI incidence in over 1900 children (mean age, 6 years) hospitalized at one of six children's hospitals.

All children received vancomycin plus a β-lactam antibiotic and had baseline serum creatinine measurements taken during the first 2 days of hospitalization and during days 3 to 7. AKI was defined as an increase in serum creatinine by 50% or ≥0.3 mg/dL within 2 days of the last antibiotic dose.

The incidence of antibiotic-associated AKI was 8% during …

Reviewing Author

F. Bruder Stapleton, MD

Disclosures

Consultant/Advisory BoardCareer Physician

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesAmerican Society of Pediatric Nephrology Foundation (Chair)

F. Bruder Stapleton, MD

Disclosures

Consultant/Advisory BoardCareer Physician

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesAmerican Society of Pediatric Nephrology Foundation (Chair)

Increased AKI Risk with Vancomycin plus Piperacillin/Tazobactam in Pediatric Inpatients

Topics

Reviewing Author